KRISTEN GREEN: Open Payments
NPI 1023773561 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 48 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $929
Food & beverage: $929
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $207 |
| GlaxoSmithKline, LLC. | 4 | $69 |
| ABBVIE INC. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Astellas Pharma US Inc | 3 | $61 |
| SANOFI-AVENTIS U.S. LLC | 1 | $47 |
| Amgen Inc. | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Lilly USA, LLC | 2 | $34 |
| Merck Sharp & Dohme LLC | 2 | $33 |
Products named: AIRSUPRA, FARXIGA, REXULTI, Veozah, VRAYLAR, TZIELD, TRELEGY ELLIPTA, OTEZLA.
Industry payments across DE — which companies pay providers there.
